Welcome to our updated website. Building on the outstanding success of the CSF we are evolving our services across the wider range of immune medicated inflammatory diseases with our new site. Don't forget to bookmark this page!

Over the coming months we will add in new disease areas and you will be able to choose and filter the content that is of most interest to you. For now we have updated our website to allow us to expand and you will see some new layouts and features. Please explore and let us know what you think.

Our offering has not changed: we provide unique educational materials, all for free. Thank you once again for your continued support and feedback across the years. We hope you enjoy the new website.

The Immune Mediated Inflammatory Disease Forum Team

About the Immune-Mediated Inflammatory Disease Forum

Baricitinib in Juvenile Idiopathic Arthritis: An International, Phase 3, Randomised, Double-blind, Placebo-controlled, Withdrawal, Efficacy, and Safety Trial

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease

Galapagos Receives Positive CHMP Opinion for Filgotinib European Label Update Based on Testicular Function Safety Data

FDA Approves Deucravacitinib for Adults with Moderate-to-Severe Plaque Psoriasis

Steering Committee